We are monitoring the impact of COVID-19 on Asia-Pacific Immunotherapy Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 1095
Share on
Share on

Asia Pacific Immunotherapy Drugs Market Research Report – Segmented By Drug Type, Application & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, Growth & Forecast | 2019 - 2024

Pulished: August, 2019
ID: 1095
Pages: 145

Asia Pacific Immunotherapy Drugs Market Size & Growth (2019 – 2024):

The Size of the Asia Pacific Immunotherapy Drugs Market is valued at USD 11.7 billion in 2019 and is poised to reach USD 21.08 billion by 2024,  growing at a tremendous CAGR of 12.5% during the forecast period 2019-2024.

The usage of immunotherapy drugs is rising with increasing cancer incidences and autoimmune diseases and is estimated to witness a positive outlook in the forecast period.

Immunotherapy is a process of enhancing your innate power of the immune system to fight against cancer cells. It either counteracts the signal which is produced by the cancer cells and suppress the responses by the immune system or stimulate the specific components of the immune system. These properties of the immunotherapies make them treat diseases involving infection, cancer, respiratory and autoimmune disorders.

The rising occurrence of cancer and autoimmune diseases coupled with technological advancements has led to the innovation of new drugs with higher efficiency than the existing drugs. Increasing cancer cases with changing demographics, fewer side effects with higher efficacy, acceleration of drug development process and testing are the primary driving factors for the growth of the market. However, factors including high prices of drugs and less accessibility are dampening the growth of the market.

Asia Pacific Immunotherapy Drugs Market has been segmented and sub-segmented into the following categories

  • By Drug Type: Monoclonal antibodies, Interferons, Interleukins, Vaccines, checkpoint inhibitors.
  • By Application: Blood Cancer, Cervical Cancer, Breast Cancer, Glioblastoma, Lung Cancer, Gastric Cancer, Prostate Cancer, Melanoma.
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC

Prominent Companies dominating the Asia Pacific Immunotherapy Drugs Market Profiled in the Report are Roche, Merck, Eli Lilly, Novartis, AstraZeneca, GlaxoSmithKline PLC, Amgen, Celgene, Bristol Myers Squibb, and Seattle Genetics.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Drug Type                             

                                5.1.1 Monoclonal Antibodies     

                                5.1.2 Interferons             

                                5.1.3 Interleukins            

                                5.1.4 Vaccines  

                                5.1.5 Checkpoint Inhibitors         

                5.2 By Application                           

                                5.2.1 Blood Cancer         

                                5.2.2 Cervical Cancer     

                                5.2.3 Breast Cancer        

                                5.2.4 Glioblastoma         

                                5.2.5 Lung Cancer           

                                5.2.6 Gastric Cancer       

                                5.2.7 Prostate Cancer    

                                5.2.8 Melanoma              

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7. Pipeline Product Analysis                                        

                7.1 Overview                                    

                7.2 Pipeline Development Landscape                                     

                7.3 Molecular Targets in the Pipeline                                     

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                 

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.               

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9. Market Leaders' Analysis                                        

                9.1 Eli Lilly                           

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck                           

                9.3 Roche                           

                9.4 Amgen                         

                9.5 Novartis                       

                9.6 Celgene                       

                9.7 AstraZeneca               

                9.8 Bristol Myers Squibb                              

                9.9 GlaxoSmithKline PLC                              

                9.10 Seattle Genetics                    

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11. Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Immunotherapy Drugs Market By Region, From 2019-2024 (USD Billion)
  2. Asia-Pacific Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  3. Asia-Pacific Monoclonal Antibodies Market By Region, From 2019-2024 (USD Billion)
  4. Asia-Pacific Interferons Market By Region, From 2019-2024 (USD Billion)
  5. Asia-Pacific Interleukins Market By Region, From 2019-2024 (USD Billion)
  6. Asia-Pacific Vaccines Market By Region, From 2019-2024 (USD Billion)
  7. Asia-Pacific Checkpoint Inhibitors Market By Region, From 2019-2024 (USD Billion)
  8. Asia-Pacific Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  9. Asia-Pacific Blood Cancer Market By Region, From 2019-2024 (USD Billion)
  10. Asia-Pacific Cervical Cancer Market By Region, From 2019-2024 (USD Billion)
  11. Asia-Pacific Breast Cancer Market By Region, From 2019-2024 (USD Billion)
  12. Asia-Pacific Glioblastoma Market By Region, From 2019-2024 (USD Billion)
  13. Asia-Pacific Lung Cancer Market By Region, From 2019-2024 (USD Billion)
  14. Asia-Pacific Gastric Cancer Market By Region, From 2019-2024 (USD Billion)
  15. Asia-Pacific Prostate Cancer Market By Region, From 2019-2024 (USD Billion)
  16. Asia-Pacific Melanoma Market By Region, From 2019-2024 (USD Billion)
  17. China Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  18. China Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  19. India Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  20. India Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  21. Japan Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  22. Japan Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  23. South Korea Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  24. South Korea Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)
  25. Australia Immunotherapy Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  26. Australia Immunotherapy Drugs Market By Application, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample